SWX:NOVN.SW

Novartis announces expansion of community health programs to close gaps in heart disease and cancer care, targeting more than 30 countries by 2030

Strengthens three community health models spanning community‑embedded care, earlier intervention and data‑driven population healthScales program footprint from 11 countries to…

1 day ago

Novartis IgAN data in New England Journal of Medicine show Fabhalta slowed kidney function decline by 49.3%

“Persistent kidney inflammation is a hallmark of IgAN, and a key driver of disease progression, leading to ongoing kidney damage…

2 weeks ago

Novartis Cosentyx receives FDA approval for pediatric patients aged 12+ with moderate to severe hidradenitis suppurativa

Cosentyx is the only IL-17A inhibitor approved for this population, and the first differentiated mechanism in nearly a decade1-3 HS often emerges around…

4 weeks ago

Novartis breaks ground on new global Biomedical Research center in San Diego to accelerate drug discovery

New facility will enable end‑to‑end discovery across key disease areas and technology platforms, joining existing global research sites including Cambridge,…

2 months ago